This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synergy Pharmaceuticals Announces Change In Presentation Time At Jefferies 2013 Global Healthcare Conference

NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced a change in the Company's presentation time at the 2013 Jefferies Global Healthcare Conference being held in New York City. President and CEO, Gary S. Jacob, Ph.D., will present on Thursday, June 6, 2013, at 1:30 p.m. (ET) at the Grand Hyatt New York.

Live audio webcast of the presentation will be available under the investor relations section of Synergy's website at www.synergypharma.com . A replay of the presentation will also be available and archived on the site for 60 days.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal (GI) diseases and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human GI hormone, uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, a positive Phase IIa and a large multicenter clinical trial in patients with chronic idiopathic constipation. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has recently completed its first Phase I trial in healthy volunteers. More information is available at www.synergypharma.com

CONTACT: Media Contact:
         
         Gem Gokmen
         Office:  212-584-7610
         Mobile:  646-637-3208
         ggokmen@synergypharma.com
         
         Investor Contact:
         
         Bernard Denoyer
         Office: 212-297-0020
         Mobile: 203-300-8147
         Bdenoyer@synergypharma.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs